BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
March 25, 2026 - 01:51
POMPANO BEACH, Fla., March 24, 2026 – BioStem Technologies, Inc., a leader in regenerative medicine, has released its financial results for the fourth quarter and full year ended December 31, 2025. The company, which specializes in perinatal tissue allograft products, reported robust financial metrics for the period.
A key highlight from the report was the generation of $10.1 million in net revenue during the fourth quarter of 2025. The company achieved an exceptionally high gross margin of 97% for that quarter, underscoring the strength of its operational model and product portfolio.
Further solidifying its market position and growth trajectory, BioStem Technologies successfully completed a strategic acquisition. This move is anticipated to enhance the company's capabilities and expand its commercial reach within the regenerative medicine sector. The financial results reflect a period of significant execution and strategic advancement for the company as it continues to focus on developing and commercializing innovative biological solutions for wound care and tissue repair.
MORE NEWS
March 24, 2026 - 04:52
Iran issues its largest-ever currency denomination as accelerating inflation ravages a financial sector deemed a ‘Ponzi scheme’ even before the warIran has unveiled its highest-value banknote ever, a stark response to an inflation crisis so severe that physical currency is now in critically short supply. The move highlights the profound...
March 23, 2026 - 13:43
Bonds Decoupling From Oil Amid Longer Conflict FearsFinancial markets are witnessing a notable shift as government bonds begin to move independently from their recent correlation with crude oil prices. This decoupling suggests investors are focusing...
March 22, 2026 - 22:10
Is Mitsubishi UFJ Financial Group (TSE:8306) Still Attractive After Recent Share Price Pullback?Investors are closely examining Mitsubishi UFJ Financial Group (MUFG) following a notable retreat in its share price. The stock recently closed at ¥2,686, reflecting a significant 10.7% drop over...
March 22, 2026 - 05:57
Down 23% This Year, Is It Finally Time to Buy Snowflake Stock?After a significant 23% decline in its stock price this year, Snowflake is capturing renewed attention from the market. The recent catalyst is the company`s impressive fiscal fourth-quarter...